CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. [electronic resource]
Producer: 20120301Description: 208-12 p. digitalISSN:- 1468-2079
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Complement Factor H -- genetics
- Female
- Fluorescein Angiography
- Genotype
- High-Temperature Requirement A Serine Peptidase 1
- Humans
- Indocyanine Green
- Intravitreal Injections
- Male
- Pilot Projects
- Polymerase Chain Reaction
- Polymorphism, Single Nucleotide
- Promoter Regions, Genetic -- genetics
- Ranibizumab
- Serine Endopeptidases -- genetics
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- genetics
- Visual Acuity -- physiology
- Wet Macular Degeneration -- drug therapy
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.